Analytical performance evaluation and enhancement of the ADVIA Centaur® HIV Ag/Ab Combo assay.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
09 2019
Historique:
received: 14 06 2019
revised: 22 07 2019
accepted: 24 07 2019
pubmed: 16 8 2019
medline: 17 6 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

Fourth-generation immunoassays (such as the ADVIA Centaur® HIV Ag/Ab Combo (CHIV) assay) have improved the early diagnosis of human immunodeficiency virus (HIV), and their sensitivity and specificity usually exceed 99%. In regions with a low prevalence of HIV infection, however, the regular occurrence of false positives interferes with a medical laboratory's workflow. The additional reagent and staff costs associated with false positives can nevertheless be avoided or reduced by gaining a better knowledge of the CHIV assay's performance. To improve our HIV diagnosis strategy, we retrospectively analyzed all the Centaur® CHIV assays and confirmatory tests performed at Amiens University Medical Center between 2012 and 2018. We used open-source machine learning software to process this large database, develop a predictive model, and identify a new cut-off for Centaur® CHIV index interpretation. A total of 56,682 HIV serological assay results were analyzed. The results of the CHIV assay were initially reactive or indeterminate for 449 samples. After p24 antigen and/or immunoblotting, there were 171 (38%) false positives and 278 (62%) confirmed true positives. The application of a cut-off of 2.12 led to reclassification of 130 of the 171 false positives as true negatives. Combining our predictive model with medical record analysis reduced the number of false positive CHIV assay results from 171 to 12. The efficiency of the Centaur® CHIV assay can be increased by adjusting its cut-off for positivity. This adjustment may reduce the number of unnecessary confirmatory tests and accelerate the delivery of HIV test results.

Sections du résumé

BACKGROUND
Fourth-generation immunoassays (such as the ADVIA Centaur® HIV Ag/Ab Combo (CHIV) assay) have improved the early diagnosis of human immunodeficiency virus (HIV), and their sensitivity and specificity usually exceed 99%. In regions with a low prevalence of HIV infection, however, the regular occurrence of false positives interferes with a medical laboratory's workflow. The additional reagent and staff costs associated with false positives can nevertheless be avoided or reduced by gaining a better knowledge of the CHIV assay's performance.
OBJECTIVES/STUDY DESIGN
To improve our HIV diagnosis strategy, we retrospectively analyzed all the Centaur® CHIV assays and confirmatory tests performed at Amiens University Medical Center between 2012 and 2018. We used open-source machine learning software to process this large database, develop a predictive model, and identify a new cut-off for Centaur® CHIV index interpretation.
RESULTS
A total of 56,682 HIV serological assay results were analyzed. The results of the CHIV assay were initially reactive or indeterminate for 449 samples. After p24 antigen and/or immunoblotting, there were 171 (38%) false positives and 278 (62%) confirmed true positives. The application of a cut-off of 2.12 led to reclassification of 130 of the 171 false positives as true negatives. Combining our predictive model with medical record analysis reduced the number of false positive CHIV assay results from 171 to 12.
CONCLUSIONS
The efficiency of the Centaur® CHIV assay can be increased by adjusting its cut-off for positivity. This adjustment may reduce the number of unnecessary confirmatory tests and accelerate the delivery of HIV test results.

Identifiants

pubmed: 31415958
pii: S1386-6532(19)30165-9
doi: 10.1016/j.jcv.2019.07.007
pii:
doi:

Substances chimiques

HIV Antibodies 0
HIV Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-40

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Baptiste Demey (B)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.

Cédric Usureau (C)

Department of Oncobiology, Amiens University Medical Center, Amiens, France.

Paul Boillod (P)

Department of Virology, Amiens University Medical Center, Amiens, France.

Sandra Bodeau (S)

Laboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.

Catherine François (C)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.

Catherine Roussel (C)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.

Gilles Duverlie (G)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.

Sandrine Castelain (S)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.

Etienne Brochot (E)

Department of Virology, Amiens University Medical Center, Amiens, France; AGIR Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France. Electronic address: etienne.brochot@u-picardie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH